Interferon-α versus interleukin-2 in Chinese patients with malignant melanoma: a randomized, controlled, trial

The US Food and Drug Association has approved interferon-α (IFN-α) and interleukin-2 (IL-2) as adjuvant therapy in malignant melanoma. The objective of the study was to compare efficacy and safety of subcutaneous interferon-α with continuous intravenous IL-2 in Chinese patients with malignant melano...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shenglong, Wu, Xixi, Chen, Peng, Pei, Yi, Zheng, Ke, Wang, Wei, Qiu, Enduo, Zhang, Xiaojing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Clinical Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430598/
https://www.ncbi.nlm.nih.gov/pubmed/30664008
http://dx.doi.org/10.1097/CAD.0000000000000741

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430598/
https://www.ncbi.nlm.nih.gov/pubmed/30664008
http://dx.doi.org/10.1097/CAD.0000000000000741

Ejemplares similares